Zhou et al. (Zhou et al., 2022) reported that patients with CD79B and/or PIM1 mutations had a significantly longer 2-year OS (76 and 40%, p = 0.0372) than those without CD79B/PIM1 mutations in primary CNS DLBCL patients. Here, CD79B is linked to diffuse large B-cell lymphoma of the central nervous system.